



Regenerative Medicine in Diabetes

Guest Editor:

Dr. Shoichiro Sumi

Institute for Frontier Life and
Medical Sciences, Kyoto
University, 53 Shogoin-Kawara-
cho, Sakyo-ku, Kyoto 606-8507,
Japan

Deadline for manuscript
submissions:

closed (31 July 2020)

Message from the Guest Editor

Diabetes mellitus (DM) is caused by an insufficient function of insulin. Thus, if the definition of regenerative medicine is to cure diseases or injuries by reconstructing lost forms and/or functions, regenerative medicine for diabetes is to cure DM by reconstructing the function of insulin. As Dr. Banting stated almost a century ago in a Nobel lecture, exogenous insulin administration is not a cure for diabetes but a treatment. In that sense, transplantation of the pancreas organ or isolated islets can cure DM by reconstructing insulin action. However, current transplantation therapy for DM needs immunosuppression and human donors. Regenerative medicine can achieve similar effects without these necessities. Regenerative medicine may also prevent autoimmunity and/or islet disfunction developing DM. In this Special Issue on “Regenerative Medicine in Diabetes”, I would like to sum up our achievements and open a new vista for the future in this field. Original investigations and review articles are both welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI